Stock Track | Praxis Precision Medicines Plummets 5.4% Following Disappointing Q4 Earnings and Financial Update

Stock Track

03/06

Shares of Praxis Precision Medicines, Inc. (PRAX) plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.

According to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in some of its key programs.

The disappointing financial performance and bleak outlook appear to have rattled investors, leading to the significant sell-off in PRAX stock. Analysts warn that the company may face challenges in raising additional capital or securing partnerships if its drug development efforts continue to falter.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1162846292"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162846292\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162846292?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162846292","market":"us","top_or_hot":-1,"title":"Stock Track | Praxis Precision Medicines Plummets 5.4% Following Disappointing Q4 Earnings and Financial Update","media":"Stock Track","content":"<p>Shares of Praxis Precision Medicines, Inc. (PRAX) plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.</p>\n\n<p>According to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in some of its key programs.</p>\n\n<p>The disappointing financial performance and bleak outlook appear to have rattled investors, leading to the significant sell-off in PRAX stock. Analysts warn that the company may face challenges in raising additional capital or securing partnerships if its drug development efforts continue to falter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Praxis Precision Medicines Plummets 5.4% Following Disappointing Q4 Earnings and Financial Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Praxis Precision Medicines Plummets 5.4% Following Disappointing Q4 Earnings and Financial Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-06 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Praxis Precision Medicines, Inc. (PRAX) plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.</p>\n\n<p>According to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in some of its key programs.</p>\n\n<p>The disappointing financial performance and bleak outlook appear to have rattled investors, leading to the significant sell-off in PRAX stock. Analysts warn that the company may face challenges in raising additional capital or securing partnerships if its drug development efforts continue to falter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"","article_id":"1162846292","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162846292","pubTimestamp":1741271924,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Praxis Precision Medicines, Inc.  plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.According to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in so","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"Praxis Precision Medicines第四季度盈利和财务更新令人失望，股价暴跌5.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"Shares of Praxis Precision Medicines, Inc. (PRAX) plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.\nAccording to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in some of its key programs.\nThe disappointing financial performance and bleak outlook appear to have rattled investors, leading to the significant sell-off in PRAX stock. Analysts warn that the company may face challenges in raising additional capital or securing partnerships if its drug development efforts continue to falter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}